Reportlinker Adds U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2010
NEW YORK, Jan. 12 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2010
There are currently over 23.6 million people in the U.S., or almost 8% of the population who have diabetes. The diabetes market is expected to show substantial growth due to the obesity epidemic in the U.S., now becoming known as diabesity. This report covers the U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery, which includes:
- blood glucose diagnosis and monitoring including traditional blood glucose monitors
- continuous glucose monitoring systems (CGM),
- blood glucose test strips
- lancets and lancing devices
This market also includes the markets for insulin and insulin delivery devices including syringes, pens, pumps and jet injectors as well as oral anti-diabetic drugs.
Over the forecast period, the U.S. market for diabetes drugs, devices and monitoring systems is expected to grow at double-digit rates, reaching a value of over $55 billion by 2016. The market for insulin will grow over 18% in 2009, while continuous glucose monitoring systems will see growth of 48%. This report provides a comprehensive analysis of the blood glucose monitoring, insulin delivery and antidiabetic drug markets.
Within the diabetic devices market, companies such as Abbott, Bayer, Eli Lilly, Lifescan, Medtronic and Roche lead the market. This report also covers the insulin market as well as oral and injectable antidiabetic drugs. Oral drugs are estimated to see double-digit growth through 2016, with companies such as Amylin, Bristol-Myers, Squibb, GlaxoSmithKline, Merck & Co., Novo Nordisk, Pfizer and Takeda leading the market. This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2016, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.
TABLE OF CONTENTS ........ I
LIST OF FIGURES ........... VIII
LIST OF CHARTS ............ XIII
EXECUTIVE SUMMARY ...18
1.1 U.S. MARKET FOR DIABETES DIAGNOSIS, TREATMENT AND DRUG DELIVERY......... 18
1.2 TREND ANALYSIS BY SEGMENT .......... 19
1.3 BLOOD GLUCOSE MONITORING MARKET .................. 20
1.4 DIABETIC POPULATION .......... 21
1.5 INSULIN 22
1.6 INSULIN SYRINGES ...... 23
1.7 INSULIN PENS .............. 24
1.8 INSULIN PUMPS ........... 24
1.9 ORAL ANTIDIABETIC DRUGS . 25
1.9.1 Price Analysis ....... 25
1.9.2 Market Analysis .... 26
1.10 LEADING COMPETITORS IN THE DIABETES DEVICES MARKET ......... 27
1.11 LEADING COMPETITORS IN THE INSULIN AND ANTIDIABETIC DRUG MARKET........ 28
RESEARCH METHODOLOGY ....29
2.1 RESEARCH SCOPE ....... 29
2.2 IDATA'S 9-STEP METHODOLOGY ........ 29
Step 1: Project Initiation & Team Selection ............... 30
Step 2: Prepare Data Systems and Perform Secondary Research ....... 31
Step 3: Preparation for Interviews & Questionnaire Design 32
Step 4: Performing Primary Research . 33
Step 5: Research Analysis: Establishing Baseline Estimates 35
Step 6: Market Forecast and Analysis . 35
Step 7: Identify Strategic Opportunities ..................... 37
Step 8: Final Review and Market Release .................. 38
Step 9: Customer Feedback and Market Monitoring .. 39
OVERVIEW OF DIABETES ..........40
3.1 INTRODUCTION ........... 40
3.2 MAIN TYPES OF DIABETES .... 40
3.2.1 Type 1 Diabetes .... 40
3.2.2 Type 2 Diabetes .... 40
3.2.3 Gestational Diabetes ........ 41
3.2.4 Prediabetes ........... 41
3.3 DIABETES COMPLICATIONS ... 42
3.4 RISK FACTORS ASSOCIATED WITH TYPE 1 AND TYPE 2 DIABETES ..... 44
3.5 SIGNS AND SYMPTOMS .......... 46
3.6 MONITORING .............. 47
3.6.1 Initial Diagnosis ... 47
3.6.2 Blood Glucose Monitoring Systems ...................... 48
3.6.3 Urinary Glucose Monitoring ......... 49
3.6.4 Noninvasive and Minimally Invasive Monitoring Devices ............ 49
3.7 TREATMENT ................ 50
3.7.1 Lifestyle Measures 50
3.7.2 Insulin ................... 51
3.7.3 Oral Antidiabetic Drugs .. 51
3.7.4 Injectable Antidiabetic Drugs ........ 52
3.8 DRUG DELIVERY ......... 52
3.8.1 Insulin Syringes ..... 52
3.8.2 Insulin Pens ........... 52
3.8.3 Insulin Pumps ....... 52
3.8.4 Inhaled Insulin ...... 53
3.8.5 Insulin Patches ...... 53
3.9 EMERGING TECHNOLOGIES ... 54
3.10 MARKET OVERVIEW . 55
3.11 MARKET ANALYSIS BY SEGMENT ..... 57
3.12 TREND ANALYSIS AND FORECAST BY SEGMENT ...... 61
3.13 MARKET DRIVERS AND LIMITERS ..... 64
3.13.1 Market Drivers .... 64
3.13.2 Market Limiters ... 65
3.14 COMPETITIVE ANALYSIS ..... 67
DIABETES IN THE U.S. ......77
4.1 DIABETES PREVALENCE ........ 77
4.2 DIABETES INCIDENCE . 80
4.3 DIABETES DEMOGRAPHICS .... 82
4.4 OBESITY PREVALENCE .......... 85
TRADITIONAL BLOOD GLUCOSE METERS ...............89
5.1 INTRODUCTION ........... 89
5.2 MARKET ANALYSIS AND FORECAST ... 90
5.2.1 Total Blood Glucose Monitoring Market .............. 90
5.2.2 Total Traditional Blood Glucose Meter Market ... 93
5.2.3 Professional Traditional Blood Glucose Meter Market .. 96
5.2.4 Personal Traditional Blood Glucose Meter Market ........ 99
5.3 MARKET DRIVERS AND LIMITERS ..... 102
5.3.1 Market Drivers .... 102
5.3.2 Market Limiters ... 103
5.4 COMPETITIVE ANALYSIS ..... 105
CONTINUOUS GLUCOSE MONITORING SYSTEMS 108
6.1 INTRODUCTION ......... 108
6.2 MARKET ANALYSIS AND FORECAST . 109
6.2.1 Total Blood Glucose Monitoring Market ............ 109
6.2.2 Continuous Glucose Monitoring System Market 112
6.3 MARKET DRIVERS AND LIMITERS ..... 114
6.3.1 Market Drivers .... 114
6.3.2 Market Limiters ... 115
6.4 COMPETITIVE ANALYSIS ..... 118
BLOOD GLUCOSE TEST STRIPS ...........120
7.1 INTRODUCTION ......... 120
7.2 MARKET ANALYSIS AND FORECAST . 121
7.2.1 Total Blood Glucose Monitoring Market ............ 121
7.2.2 Diabetic Population Using Blood Glucose Monitor Test Strips .. 124
7.2.3 Total Blood Glucose Test Strip Market .............. 125
7.2.4 Professional Blood Glucose Test Strip Market ... 127
7.2.5 Personal Blood Glucose Test Strip Market ........ 129
7.3 MARKET DRIVERS AND LIMITERS ..... 131
7.3.1 Market Drivers .... 131
7.3.2 Market Limiters ... 132
7.4 COMPETITIVE ANALYSIS ..... 134
LANCETS AND LANCING DEVICES .....137
8.1 INTRODUCTION ......... 137
8.2 MARKET ANALYSIS AND FORECAST . 138
8.2.1 Total Blood Glucose Monitoring Market ............ 138
8.2.2 Total Lancet and Lancing Device Market .......... 140
8.2.3 Professional Lancet and Lancing Device Market .......... 143
8.2.4 Personal Lancet and Lancing Device Market .... 146
8.3 MARKET DRIVERS AND LIMITERS ..... 149
8.3.1 Market Drivers .... 149
8.3.2 Market Limiters ... 150
8.4 COMPETITIVE ANALYSIS ..... 152
INSULIN .......155
9.1 INTRODUCTION ......... 155
9.1.1 Insulin Types ....... 155
9.2 MARKET ANALYSIS AND FORECAST . 159
9.2.1 Total Insulin Market ...... 159
9.2.2 Rapid-Acting Insulin Analogs ...... 163
9.2.3 Regular and Intermediate-Acting Human Insulin .......... 165
9.2.4 Long-Acting Insulin Analog ......... 167
9.2.5 Insulin Mixtures .. 169
9.3 MARKET DRIVERS AND LIMITERS ..... 171
9.3.1 Market Drivers .... 171
9.3.2 Market Limiters ... 172
9.4 COMPETITIVE ANALYSIS ..... 174
INSULIN SYRINGES .........177
10.1 INTRODUCTION ....... 177
10.2 MARKET ANALYSIS AND FORECAST ...................... 178
10.2.1 Total Insulin Syringe Market ..... 178
10.2.2 Professional Insulin Syringe Market ................ 180
10.2.3 Personal Insulin Syringe Market ...................... 182
10.3 MARKET DRIVERS AND LIMITERS ... 184
10.3.1 Market Drivers .. 184
10.3.2 Market Limiters . 185
10.4 COMPETITIVE ANALYSIS ... 187
INSULIN PENS ...................190
11.1 INTRODUCTION ....... 190
11.2 MARKET ANALYSIS AND FORECAST ...................... 191
11.3 MARKET DRIVERS AND LIMITERS ... 193
11.3.1 Market Drivers .. 193
11.3.2 Market Limiters . 194
11.4 COMPETITIVE ANALYSIS ... 196
INSULIN PUMPS ................198
12.1 INTRODUCTION ....... 198
12.2 MARKET ANALYSIS AND FORECAST ...................... 200
12.2.1 Total Insulin Pump and Insulin Pump Infusion Set Market ....... 200
12.2.2 Insulin Pump Market ... 202
12.2.3 Insulin Pump Infusion Set Market ..................... 204
12.3 MARKET DRIVERS AND LIMITERS ... 206
12.3.1 Market Drivers .. 206
12.3.2 Market Limiters . 208
12.4 COMPETITIVE ANALYSIS ... 210
ORAL ANTIDIABETIC DRUGS .212
13.1 INTRODUCTION ....... 212
13.2 MARKET ANALYSIS AND FORECAST ...................... 223
13.2.1 Total Oral Antidiabetic Drug Market ............... 223
13.2.1.1 Unit Analysis 223
13.2.1.2 Price Analysis .........224
13.2.1.3 Market Analysis ......226
13.2.2 Alpha-Glucosidase Inhibitors .... 230
13.2.3 Biguanides ........ 233
13.2.3.1 Total Biguanide Market ........233
13.2.3.2 Brand Name Biguanide Market ...................236
13.2.3.3 Generic Biguanide Market ...238
13.2.4 DPP-IV Inhibitors ........ 240
13.2.5 Sulfonylureas .... 243
13.2.5.1 Total Sulfonylurea Market ....243
13.2.5.2 Brand Name Sulfonylurea Market ...............246
13.2.5.3 Generic Sulfonylurea Market ......................248
13.2.6 Meglitinides ...... 250
13.2.7 Thiazolidinediones ....... 253
13.2.8 Single Pill Combinations ........... 256
13.3 MARKET DRIVERS AND LIMITERS ... 259
13.3.1 Market Drivers .. 259
13.3.2 Market Limiters . 261
13.4 COMPETITIVE ANALYSIS ... 263
INJECTABLE ANTIDIABETIC DRUGS .268
14.1 INTRODUCTION ....... 268
14.2 MARKET ANALYSIS AND FORECAST ...................... 272
14.2.1 Total Injectable Antidiabetic Drug Market ....... 272
14.2.1.1 Unit Analysis 272
14.2.1.2 Price Analysis .........273
14.2.1.3 Market Analysis ......274
14.2.2 GLP-1 Receptor Agonists .......... 278
14.2.3 Amylinomimetics .......... 281
14.3 MARKET DRIVERS AND LIMITERS ... 283
14.3.1 Market Drivers .. 283
14.3.2 Market Limiters . 284
14.4 COMPETITIVE ANALYSIS ... 286
ABBREVIATIONS ..............288
LIST OF FIGURES
EXECUTIVE SUMMARY ........... 18
RESEARCH METHODOLOGY ... 29
OVERVIEW OF DIABETES ....... 40
Figure 3-1: Major Types of Diabetes and Related Pathologies ..... 42
Figure 3-2: Risk Factors Associated with Type 1 and Type 2 Diabetes ............... 46
Figure 3-3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes ... 47
Figure 3-4: Blood Glucose Ranges Recommended by the American Diabetes
Association (ADA), U.S., 2009 ...................... 49
Figure 3-5: Total Diabetes Diagnosis, Treatment and Drug Delivery Market by
Segment, U.S., 2006 – 2016 .... 58
Figure 3-6: Trend Analysis, Growth Rates by Market Segment, U.S. Market for
Diabetics Diagnosis, Treatment and Drug Delivery, 2006 – 2016 .................... 62
Figure 3-7: Drivers and Limiters in the U.S. Market for Diabetes Diagnosis,
Treatment and Drug Delivery, 2009 ............... 66
Figure 3-8: Leading Competitors in the Diabetes Diagnosis, Monitoring,
Treatment and Drug Delivery Market, U.S., 2006 – 2016 (Part 1) ................... 70
Figure 3-9: Leading Competitors in the Diabetes Diagnosis, Monitoring,
Treatment and Drug Delivery Market, U.S., 2006 – 2016 (Part 2) ................... 71
Figure 3-10: Leading Competitors in the Devices Segment of the Total Market
for Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009 .................. 73
Figure 3-11: Leading Competitors in the Insulin and Antidiabetic Drug Segment
of the Total Market for Diabetes Diagnosis, Treatment and Drug Delivery,
U.S., 2009 ..... 75
DIABETES IN THE U.S. ............ 77
Figure 4-1: Total Prevalence of Diabetes Both Diagnosed and Undiagnosed,
Adults Aged 18 – 79, U.S., 2006 – 2016 ......... 78
Figure 4-2: Incidence of Diabetes in Adults Aged 18 – 79, U.S., 2006 – 2016 .... 80
Figure 4-3: Percentage of Population Diagnosed with Diabetes by Race and Sex,
U.S., 2006 – 2016 ..... 83
Figure 4-4: Obesity Prevalence in Adults by State, Alabama to Mississippi,
U.S., 2008 (Part 1) .... 86
Figure 4-5: Obesity Prevalence in Adults by State, Missouri to Wyoming, U.S.,
2008 (Part 2) . 87
TRADITIONAL BLOOD GLUCOSE METERS .. 89
Figure 5-1: Blood Glucose Ranges Recommended by the American Diabetes
Association (ADA), U.S., 2009 ...................... 89
Figure 5-2: Total Blood Glucose Monitoring Market, U.S., 2006 – 2016 ............ 91
Figure 5-3: Total Traditional Blood Glucose Meter Market by Segment, U.S.,
2006 – 2016 ... 94
Figure 5-4: Professional Traditional Blood Glucose Meter Market, U.S., 2006 –
2016 .............. 97
Figure 5-5: Personal Traditional Blood Glucose Meter Market, U.S., 2006 –
2016 ............ 100
Figure 5-6: Drivers and Limiters, Traditional Blood Glucose Meter Market,
U.S., 2009 ... 104
Figure 5-7: Leading Competitors in the Traditional Blood Glucose Meter
Market, U.S., 2009 . 106
CONTINUOUS GLUCOSE MONITORING SYSTEMS 108
Figure 6-1: Total Blood Glucose Monitoring Market, U.S., 2006 – 2016 .......... 110
Figure 6-2: Continuous Glucose Monitoring System Market, U.S., 2006 – 2016112
Figure 6-3: Drivers and Limiters, Continuous Glucose Monitoring System
Market, U.S., 2009 . 117
Figure 6-4: Leading Competitors in the Continuous Glucose Monitoring System
Market, U.S., 2009 . 118
BLOOD GLUCOSE TEST STRIPS ................... 120
Figure 7-1: Total Blood Glucose Monitoring Market, U.S., 2006 – 2016 .......... 122
Figure 7-2: Diabetic Population Using Blood Glucose Monitor Test Strips, U.S.,
2006 – 2016 . 124
Figure 7-3: Total Blood Glucose Test Strip Market by Segment, U.S., 2006 –
2016 ............ 125
Figure 7-4: Professional Blood Glucose Test Strip Market by Segment, U.S.,
2006 – 2016 . 127
Figure 7-5: Personal Blood Glucose Test Strip Market by Segment, U.S., 2006 –
2016 ............ 129
Figure 7-6: Drivers and Limiters, Blood Glucose Test Strips Market, U.S., 2009133
Figure 7-7: Leading Competitors in the Blood Glucose Test Strips Market, U.S.,
2009 ............ 135
LANCETS AND LANCING DEVICES ............. 137
Figure 8-1: Total Blood Glucose Monitoring Market, U.S., 2006 – 2016 .......... 138
Figure 8-2: Total Market for Lancets and Lancing Devices by Segment, U.S.,
2006 – 2016 . 141
Figure 8-3: Professional Market for Lancets and Lancing Devices, U.S., 2006 –
2016 ............ 144
Figure 8-4: Personal Market for Lancets and Lancing Devices, U.S., 2006 –
2016 ............ 147
Figure 8-5: Drivers and Limiters, Lancet and Lancing Device Market, U.S.,
2009 ............ 151
Figure 8-6: Leading Competitors in the Lancet and Lancing Device Market,
U.S., 2009 ... 153
INSULIN ......... 155
Figure 9-1: Onset, Peak and Duration of Insulin Types, U.S., 2009 .................. 156
Figure 9-2: Brand Name Insulin, U.S., 2009 .... 158
Figure 9-3: Total Market for Insulin by Segment, U.S., 2006 – 2016 ................ 161
Figure 9-4: Rapid-Acting Insulin Analog Market, U.S., 2006 – 2016 ................ 163
Figure 9-5: Regular and Intermediate-Acting Human Insulin Market, U.S., 2006
– 2016 ......... 165
Figure 9-6: Long-Acting Insulin Analog Market, U.S., 2006 – 2016 ................. 167
Figure 9-7: Insulin Mixture Market, U.S., 2006 – 2016 ............. 169
Figure 9-8: Drivers and Limiters for the Insulin Market, U.S., 2009 ................. 173
Figure 9-9: Leading Competitors in the Insulin Market, U.S., 2009 .................. 175
INSULIN SYRINGES . 177
Figure 10-1: Total Market for Insulin Syringes by Segment, U.S., 2006 – 2016 . 178
Figure 10-2: Professional Market for Insulin Syringes, U.S., 2006 – 2016 ......... 180
Figure 10-3: Personal Market for Insulin Syringes, U.S., 2006 – 2016 ............... 182
Figure 10-4: Drivers and Limiters for the Insulin Syringe Market, U.S., 2009... 186
Figure 10-5: Leading Competitors in the Total Insulin Syringe Market, U.S.,
2009 ............ 188
INSULIN PENS .......... 190
Figure 11-1: Insulin Pens Market, U.S., 2006 – 2016 ... 191
Figure 11-2: Drivers and Limiters for the Insulin Pen Market, U.S., 2009......... 195
Figure 11-3: Leading Competitors in the Insulin Pen Market, U.S., 2009 .......... 196
INSULIN PUMPS ....... 198
Figure 12-1: Total Market for Insulin Pumps and Insulin Pump Infusion Sets by
Segment, U.S., 2006 – 2016 .. 200
Figure 12-2: Insulin Pump Market, U.S., 2006 – 2016 . 202
Figure 12-3: Insulin Pump Infusion Set Market, U.S., 2006 – 2016 .................. 204
Figure 12-4: Drivers and Limiters for the Insulin Pump Market, U.S., 2009...... 209
Figure 12-5: Leading Competitors in the Insulin Pump Market, U.S., 2009 ....... 210
ORAL ANTIDIABETIC DRUGS ...................... 212
Figure 13-1: Oral Antidiabetic Drug Overviews, U.S., 2009 ...... 214
Figure 13-2: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 1)................ 215
Figure 13-3: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 2)................ 216
Figure 13-4: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 3)................ 217
Figure 13-5: Oral Antidiabetic Drugs, U.S., 2009 (Part 1) ......... 218
Figure 13-6: Oral Antidiabetic Drugs, U.S., 2009 (Part 2) ......... 219
Figure 13-7: Adult Doses of Oral Antidiabetic Drugs, U.S., 2009 (Part 1) ........ 220
Figure 13-8: Adult Doses of Oral Antidiabetic Drugs, U.S., 2009 (Part 2) ........ 221
Figure 13-9: Oral Antidiabetic Drugs FDA Approval and Patent Expiry, U.S.,
2009 (Part 1) .......... 222
Figure 13-10: Oral Antidiabetic Drug Units, U.S., 2009 ............ 223
Figure 13-11: Oral Antidiabetic Drug Price Indices, U.S., 2009 . 225
Figure 13-12: Total Oral Antidiabetic Drug Market by Segment, U.S., 2006 –
2016 ............ 227
Figure 13-13: Alpha-Glucosidase Inhibitor Market, U.S., 2006 – 2016 ............. 231
Figure 13-14: Total Biguanide Market by Segment, U.S., 2006 – 2016 ............. 234
Figure 13-15: Brand-Name Biguanide Market, U.S., 2006 – 2016..................... 236
Figure 13-16: Generic Biguanide Market, U.S., 2006 – 2016 ..... 238
Figure 13-17: DPP-IV Inhibitor Market, U.S., 2006 – 2016 ....... 241
Figure 13-18: Total Sulfonylurea Market by Segment, U.S., 2006 – 2016 ......... 244
Figure 13-19: Brand-Name Sulfonylurea Market, U.S., 2006 – 2016................. 246
Figure 13-20: Generic Sulfonylurea Market, U.S., 2006 – 2016 . 248
Figure 13-21: Meglitinide Market, U.S., 2006 – 2016 . 251
Figure 13-22: Thiazolidinedione (TZD) Market, U.S., 2006 – 2016 .................. 254
Figure 13-23: Single Pill Combination Market, U.S., 2006 – 2016.................... 257
Figure 13-24: Drivers and Limiters for the Oral Antidiabetic Drug Market, U.S.,
2009 ............ 262
Figure 13-25: Leading Competitors in the Oral Antidiabetic Drug Market, U.S.,
2009 ............ 266
INJECTABLE ANTIDIABETIC DRUGS .......... 268
Figure 14-1: Injectable Antidiabetic Drug Indications, U.S., 2009 .................... 270
Figure 14-2: Injectable Antidiabetic Drugs, U.S., 2009 ............. 270
Figure 14-3: Injectable Antidiabetic Drugs, U.S., 2009 ............. 271
Figure 14-4: Injectable Antidiabetic Drugs, FDA Approval and Patent Expiry,
U.S., 2009 ... 271
Figure 14-5: Injectable Antidiabetic Drug Units, U.S., 2009 ...... 272
Figure 14-6: Injectable Antidiabetic Drug Price Indices, U.S., 2009 ................. 273
Figure 14-7: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2006
– 2016 ......... 275
Figure 14-8: GLP-1 Receptor Agonist Market, U.S., 2006 – 2016..................... 279
Figure 14-9: Amylinomimetic Market, U.S., 2006 – 2016 .......... 281
Figure 14-10: Drivers and Limiters for the Injectable Antidiabetic Drug Market,
U.S., 2009 ... 285
Figure 14-11: Leading Competitors in the Injectable Antidiabetic Drug Market,
U.S., 2009 ... 287
ABBREVIATIONS ..... 288
LIST OF CHARTS
EXECUTIVE SUMMARY ........... 18
Chart 1-1: Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S.,
2006 – 2016 ... 18
Chart 1-2: Fastest Growing Market Segments, Diabetes Diagnosis, Treatment and
Drug Delivery Market, U.S., 2006 – 2016 ...... 19
Chart 1-3 : Blood Glucose Test Strips as a Proportion of the Total Blood Glucose
Monitoring Market, U.S., 2009 ...................... 20
Chart 1-4: Prevalence of Diabetes Both Diagnosed and Undiagnosed, Adults
Aged 18 – 79, U.S., 2006 – 2016 .................... 21
Chart 1-5: Average Onset, Peak and Duration of Insulin Types Used in the U.S.,
2009 .............. 22
Chart 1-6: Total Market for Insulin Syringes by Segment, U.S., 2006 – 2016....... 23
Chart 1-7: Insulin Pump Market by Segment, U.S., 2006 – 2016 .. 24
Chart 1-8: Price Index Comparison, Oral Antidiabetic Drugs, U.S., 2009 ............ 25
Chart 1-9: Market Growth Analysis, Oral Antidiabetic Drugs, U.S., 2009........... 26
Chart 1-10: Leading Competitors in the Combined Market for Diabetes Devices,
U.S., 2009 ..... 27
Chart 1-11: Leading Competitors in the Combined Market for Insulin and
Antidiabetic Drugs, U.S., 2009 ...................... 28
RESEARCH METHODOLOGY ... 29
OVERVIEW OF DIABETES ....... 40
Chart 3-1: Total Diabetes Diagnosis, Treatment and Drug Delivery Market, U.S.,
2006 – 2016 ... 56
Chart 3-2: Total Diabetes Diagnosis, Monitoring, Treatment and Drug Delivery
Market by Segment, U.S., 2009 ...................... 59
Chart 3-3: Total Diabetes Diagnosis, Monitoring, Treatment and Drug Delivery
Market by Segment, U.S., 2016 ...................... 60
Chart 3-4: Fastest Growing Market Segments, Diabetes Diagnosis, Treatment
and Drug Delivery Market, U.S., 2006 – 2016 .......... 63
Chart 3-5: Leading Competitors in the Total Diabetes Diagnosis, Monitoring,
Treatment and Drug Delivery Market, U.S., 2006 – 2016 ......... 72
Chart 3-6: Leading Competitors in the Devices Segment of the Total Market for
Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009 . 74
Chart 3-7: Leading Competitors in the Insulin and Antidiabetic Drug Segment of
the Total Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S.,
2009 .............. 76
DIABETES IN THE U.S. ............ 77
Chart 4-1: Prevalence of Diabetes Both Diagnosed and Undiagnosed, Adults
Aged 18 – 79, U.S., 2006 – 2016 .................... 79
Chart 4-2: Incidence of Diabetes in Adults Aged 18 – 79, U.S., 2006 – 2016 ...... 81
Chart 4-3: Percentage of Population Diagnosed with Diabetes by Race and Sex,
U.S., 2009 ..... 84
Chart 4-4: Obesity Prevalence in Adults by State, U.S., 2008 ...... 88
TRADITIONAL BLOOD GLUCOSE METERS .. 89
Chart 5-1: Traditional Blood Glucose Monitors as a Proportion of the Total
Blood Glucose Monitoring Market, U.S., 2009 .......... 92
Chart 5-2: Total Traditional Blood Glucose Meter Market by Segment, U.S.,
2006 – 2016 ... 95
Chart 5-3: Professional Traditional Blood Glucose Meter Market, U.S., 2006 –
2016 .............. 98
Chart 5-4: Personal Traditional Blood Glucose Meter Market Segmented by
Price Range, U.S., 2009 .......... 99
Chart 5-5: Personal Traditional Blood Glucose Meter Market, U.S., 2006 – 2016101
Chart 5-6: Leading Competitors in the Blood Glucose Monitoring Device
Market, U.S., 2009 . 107
CONTINUOUS GLUCOSE MONITORING SYSTEMS 108
Chart 6-1: Continuous Glucose Monitoring Systems as a Proportion of the Total
Blood Glucose Monitoring Market, U.S., 2009 ........ 111
Chart 6-2: Continuous Glucose Monitoring System Market, U.S., 2006 – 2016 . 113
Chart 6-3: Leading Competitors in the Continuous Glucose Monitoring System
Market, U.S., 2009 . 119
BLOOD GLUCOSE TEST STRIPS ................... 120
Chart 7-1: Blood Glucose Test Strips as a Proportion of the Total Blood Glucose
Monitoring Market, U.S., 2009 .................... 123
Chart 7-2: Total Blood Glucose Test Strip Market by Segment, U.S., 2006 –
2016 ............ 126
Chart 7-3: Professional Blood Glucose Test Strip Market by Segment, U.S.,
2006 – 2016 . 128
Chart 7-4: Personal Blood Glucose Test Strip Market by Segment, U.S., 2006 –
2016 ............ 130
Chart 7-5: Leading Competitors in the Blood Glucose Test Strips Market, U.S.,
2009 ............ 136
LANCETS AND LANCING DEVICES ............. 137
Chart 8-1: Lancets and Lancing Devices as a Proportion of the Total Blood
Glucose Monitoring Market, U.S., 2009 ....... 139
Chart 8-2: Total Market for Lancets and Lancing Devices by Segment, U.S.,
2006 – 2016 . 142
Chart 8-3: Professional Market for Lancets and Lancing Devices, U.S., 2006 –
2016 ............ 145
Chart 8-4: Personal Market for Lancets and Lancing Devices, U.S., 2006 – 2016148
Chart 8-5: Leading Competitors in the Lancet and Lancing Device Market, U.S.,
2009 ............ 154
INSULIN ......... 155
Chart 9-1: Onset, Peak and Duration of Insulin Types, U.S., 2009 .................... 157
Chart 9-2: Total Market for Insulin by Segment, U.S., 2006 – 2016.................. 162
Chart 9-3: Rapid-Acting Insulin Analog Market, U.S., 2006 – 2016 ................. 164
Chart 9-4: Regular and Intermediate-Acting Human Insulin Market, U.S., 2006 –
2016 ............ 166
Chart 9-5: Long-Acting Insulin Analog Market, U.S., 2006 – 2016................... 168
Chart 9-6: Insulin Mixture Market, U.S., 2006 – 2016 . 170
Chart 9-7: Leading Competitors in the Insulin Market, U.S., 2009.................... 176
INSULIN SYRINGES . 177
Chart 10-1: Total Market for Insulin Syringes by Segment, U.S., 2006 – 2016.. 179
Chart 10-2: Professional Market for Insulin Syringes, U.S., 2006 – 2016.......... 181
Chart 10-3: Personal Market for Insulin Syringes, U.S., 2006 – 2016 ............... 183
Chart 10-4: Leading Competitors in the Total Insulin Syringe Market, U.S.,
2009 ............ 189
INSULIN PENS .......... 190
Chart 11-1: Insulin Pen Market, U.S., 2006 – 2016 ..... 192
Chart 11-2: Leading Competitors in the Insulin Pen Market, U.S., 2009 ........... 197
INSULIN PUMPS ....... 198
Chart 12-1: Total Market for Insulin Pumps and Insulin Pump Infusion Sets by
Segment, U.S., 2006 – 2016 .. 201
Chart 12-2: Insulin Pump Market, U.S., 2006 – 2016 .. 203
Chart 12-3: Insulin Pump Infusion Set Market, U.S., 2006 – 2016 .................... 205
Chart 12-4: Leading Competitors in the Insulin Pump Market, U.S., 2009 ........ 211
ORAL ANTIDIABETIC DRUGS ...................... 212
Chart 13-1: Total Oral Antidiabetic Drug Market by Segment, U.S., 2006 – 2016228
Chart 13-2: Total Oral Antidiabetic Drug Market by Segment, U.S., 2009 ........ 229
Chart 13-3: Alpha-Glucosidase Inhibitor Market, U.S., 2006 – 2016 ................ 232
Chart 13-4: Total Biguanide Market by Segment, U.S., 2006 – 2016 ................ 235
Chart 13-5: Brand Name Biguanide Market, U.S., 2006 – 2016 . 237
Chart 13-6: Generic Biguanide Market, U.S., 2006 – 2016 ........ 239
Chart 13-7: DPP-IV Inhibitor Market, U.S., 2006 – 2016 .......... 242
Chart 13-8: Total Sulfonylurea Market by Segment, U.S., 2006 – 2016 ............ 245
Chart 13-9: Brand Name Sulfonylurea Market, U.S., 2006 – 2016 .................... 247
Chart 13-10: Generic Sulfonylurea Market, U.S., 2006 – 2016 .. 249
Chart 13-11: Meglitinide Market, U.S., 2006 – 2016 ... 252
Chart 13-12: Thiazolidinedione (TZD) Market, U.S., 2006 – 2016.................... 255
Chart 13-13: Single Pill Combination Market, U.S., 2006 – 2016 ..................... 258
Chart 13-14: Leading Competitors in the Oral Antidiabetic Drug Market, U.S.,
2009 ............ 267
INJECTABLE ANTIDIABETIC DRUGS .......... 268
Chart 14-1: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2006 –
2016 ............ 276
Chart 14-2: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2009 277
Chart 14-3: GLP-1 Receptor Agonist Market, U.S., 2006 – 2016 ...................... 280
Chart 14-4: Amylinomimetic Market, U.S., 2006 – 2016 ........... 282
Chart 14-5: Leading Competitors in the Injectable Antidiabetic Drug Market,
U.S., 2009 ... 286
ABBREVIATIONS ..... 288
To order this report:
Drug Delivery Technology Industry: U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2010
Contact: |
|
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article